Hyperlactatemia in Human Immunodeficiency Virus–Uninfected Infants Who Are Exposed to Antiretrovirals
- 1 November 2004
- journal article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 114 (5) , e598-e603
- https://doi.org/10.1542/peds.2004-0955
Abstract
Objective. Exposure to nucleoside analogues in fetal or early life has been associated with rare clinically significant mitochondrial toxic effects, mainly neurologic symptoms. Lactate (LA) measurements have been used to monitor nucleoside-related mitochondrial toxicity. Our aim was to determine the prevalence, clinical evolution, and risk factors for hyperlactatemia in our cohort of human immunodeficiency virus (HIV)-uninfected children who were exposed to antiretrovirals.Keywords
This publication has 35 references indexed in Scilit:
- Hyperlactatemia in human immunodeficiency virus-infected children receiving antiretroviral treatmentThe Pediatric Infectious Disease Journal, 2003
- Lactate levels in children with HIV/AIDS on highly active antiretroviral therapyAIDS, 2003
- Case reportAIDS, 2003
- Severe Nucleoside-Associated Lactic Acidosis in Human Immunodeficiency Virus–Infected Patients: Report of 12 Cases and Review of the LiteratureClinical Infectious Diseases, 2002
- Lactacidemia in Asymptomatic HIV-Infected Subjects Receiving Nucleoside Reverse-Transcriptase InhibitorsClinical Infectious Diseases, 2002
- Symptomatic Lactic Acidosis in Hospitalized Antiretroviral‐Treated Patients with Human Immunodeficiency Virus Infection: A Report of 12 CasesClinical Infectious Diseases, 2001
- Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapyAIDS, 2000
- Hyperlactatemia and Hepatic Abnormalities in 10 Human Immunodeficiency Virus-Infected Patients Receiving Nucleoside Analogue Combination RegimensClinical Infectious Diseases, 2000
- Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophyThe Lancet, 1999
- Mitochondrial Myopathy Caused by Long-Term Zidovudine TherapyNew England Journal of Medicine, 1990